感染艾滋病毒者中的糖尿病
Diabetes in People with HIV.
作者信息
Sarkar Sudipa, Brown Todd T
机构信息
Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Asthma and Allergy Center 3B.74D, Baltimore, MD, 21224, USA.
Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, MD, 21287, USA.
出版信息
Curr Diab Rep. 2021 Mar 17;21(5):13. doi: 10.1007/s11892-021-01382-8.
Abstract
PURPOSE OF REVIEW
To discuss the diagnosis, treatment, and complications of diabetes in people with HIV (PWH) and to review HIV-related factors that may contribute to the development of diabetes or alter decisions in the care and treatment of PWH with diabetes.
RECENT FINDINGS
For those patients with atherosclerotic cardiovascular disease, heart failure, and/or chronic kidney disease, GLP-1 receptor agonists and SGLT-2 inhibitors should be considered for use. Evidence for this recommendation is, however, based on studies that were not conducted in populations consisting solely of PWH. Diabetes is a significant comorbidity in PWH and adds to their already heightened risk of cardiovascular disease. HIV-specific factors, including interactions of antiretroviral therapy with medications that either treat diabetes and/or prevent cardiovascular disease, should be evaluated.
摘要
综述目的
讨论HIV感染者（PWH）糖尿病的诊断、治疗及并发症，并回顾可能导致糖尿病发生或改变PWH糖尿病护理和治疗决策的HIV相关因素。
最新发现
对于患有动脉粥样硬化性心血管疾病、心力衰竭和/或慢性肾脏病的患者，应考虑使用胰高血糖素样肽-1（GLP-1）受体激动剂和钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂。然而，这一推荐的证据基于并非仅在PWH人群中开展的研究。糖尿病是PWH的一种重要合并症，并增加了他们本就较高的心血管疾病风险。应评估HIV特异性因素，包括抗逆转录病毒疗法与治疗糖尿病和/或预防心血管疾病药物之间的相互作用。
相似文献
1
Diabetes in People with HIV.感染艾滋病毒者中的糖尿病
Curr Diab Rep. 2021 Mar 17;21(5):13. doi: 10.1007/s11892-021-01382-8.
2
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者：临床实践指南。
BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.
3
The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists.2 型糖尿病管理的演变：SGLT-2 抑制剂和 GLP-1 受体激动剂的血糖控制及其他方面。
J Osteopath Med. 2023 Nov 3;124(3):127-135. doi: 10.1515/jom-2023-0179. eCollection 2024 Mar 1.
4
Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus.当代 2 型糖尿病患者新型心脏保护降血糖药物的资格和使用的国家模式。
J Am Heart Assoc. 2021 Jul 6;10(13):e021084. doi: 10.1161/JAHA.121.021084. Epub 2021 May 15.
5
Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者中的早期应用的理由。
Adv Ther. 2019 Oct;36(10):2567-2586. doi: 10.1007/s12325-019-01054-w. Epub 2019 Aug 23.
6
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂治疗 2 型糖尿病：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573.
7
Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.SGLT-2 抑制剂与 GLP-1 受体激动剂在 2 型糖尿病合并慢性肾脏病患者中的心血管和肾脏结局：系统评价和网络荟萃分析。
Cardiovasc Diabetol. 2021 Jan 7;20(1):14. doi: 10.1186/s12933-020-01197-z.
8
Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.SGLT-2 抑制剂与 GLP-1 受体激动剂联合治疗作为互补药物，可改善 2 型糖尿病的多器官缺陷。
Postgrad Med. 2019 Nov;131(8):555-565. doi: 10.1080/00325481.2019.1670017. Epub 2019 Oct 3.
9
Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists.用于降低 2 型糖尿病患者心血管疾病风险的药物治疗策略：重点关注 SGLT-2 抑制剂和 GLP-1 受体激动剂。
J Intern Med. 2019 Jul;286(1):16-31. doi: 10.1111/joim.12890. Epub 2019 Mar 19.
10
All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽-1 受体激动剂及其联合治疗在 2 型糖尿病患者中的全因死亡率和心血管结局。
Diabetes Obes Metab. 2023 Oct;25(10):2897-2909. doi: 10.1111/dom.15185. Epub 2023 Jun 29.
引用本文的文献
1
Dolutegravir + lamivudine effectiveness and tolerability in real-world cohorts with HIV-1 across Asia and South America: A systematic literature review.多替拉韦+拉米夫定在亚洲和南美洲HIV-1真实世界队列中的有效性和耐受性：一项系统文献综述
Medicine (Baltimore). 2025 Aug 15;104(33):e43558. doi: 10.1097/MD.0000000000043558.
2
Low-level viremia increases the risk of diabetes mellitus in people with HIV in China: a 7-year retrospective longitudinal cohort study.低水平病毒血症增加中国HIV感染者患糖尿病的风险：一项7年回顾性纵向队列研究
BMC Med. 2025 Jul 1;23(1):350. doi: 10.1186/s12916-025-04166-z.
3
Diabetes mellitus in patients with HIV naïve to antiretroviral therapy initiating integrase inhibitors therapy.在未接受过抗逆转录病毒治疗的HIV患者中，开始使用整合酶抑制剂治疗时的糖尿病。
Sci Rep. 2025 Jul 1;15(1):20439. doi: 10.1038/s41598-025-02688-3.
4
Impact of Depression and HIV Symptoms on Glycemic Outcomes among Patients with HIV and Type 2 Diabetes: A Clinical Cohort Study.抑郁症和HIV症状对HIV合并2型糖尿病患者血糖结局的影响：一项临床队列研究。
AIDS Behav. 2025 Jun;29(6):1851-1858. doi: 10.1007/s10461-025-04653-7. Epub 2025 Feb 17.
5
Deciphering the Association: Critical HDL-C Levels and Their Impact on the Glycation Gap in People Living with HIV.解读关联：HIV感染者的临界高密度脂蛋白胆固醇水平及其对糖化间隙的影响
Int J Mol Sci. 2025 Jan 22;26(3):914. doi: 10.3390/ijms26030914.
6
Nutritional risk and HbA1c as critical risk factors and predictors of opportunistic infections in HIV-DM comorbid patients: a retrospective cross-sectional study.营养风险和糖化血红蛋白作为HIV-DM合并症患者机会性感染的关键风险因素及预测指标：一项回顾性横断面研究
Front Endocrinol (Lausanne). 2025 Jan 10;15:1527936. doi: 10.3389/fendo.2024.1527936. eCollection 2024.
7
HIV clinical outcomes among people with HIV and diabetes mellitus in Kampala, Uganda; A matched retrospective cohort study.乌干达坎帕拉艾滋病毒感染者和糖尿病患者的艾滋病毒临床结局；一项匹配的回顾性队列研究。
PLOS Glob Public Health. 2025 Jan 16;5(1):e0003922. doi: 10.1371/journal.pgph.0003922. eCollection 2025.
8
Indicators associated with severity and mortality in hospitalized people with HIV: A retrospective cohort.住院艾滋病毒感染者中与严重程度和死亡率相关的指标：一项回顾性队列研究。
Rev Bras Enferm. 2025 Jan 13;77(6):e20240204. doi: 10.1590/0034-7167-2024-0204. eCollection 2025.
9
Assessment of Metabolic, Inflammatory, and Immunological Disorders Using a New Panel of Plasma Parameters in People Living with HIV Undergoing Antiretroviral Therapy-A Retrospective Study.使用一组新的血浆参数评估接受抗逆转录病毒治疗的HIV感染者的代谢、炎症和免疫紊乱——一项回顾性研究
J Clin Med. 2024 Aug 5;13(15):4580. doi: 10.3390/jcm13154580.
10
Incidence of Diabetes Mellitus and Associated Factors in the Era of Antiretroviral Drugs With a Low Metabolic Toxicity Profile.抗逆转录病毒药物时代糖尿病的发病率及相关因素，该时代药物代谢毒性较低。
Open Forum Infect Dis. 2024 Mar 1;11(4):ofae112. doi: 10.1093/ofid/ofae112. eCollection 2024 Apr.
本文引用的文献
1
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.2020年2型糖尿病患者降低心血管风险新型疗法专家共识决策路径：美国心脏病学会解决方案集监督委员会报告
J Am Coll Cardiol. 2020 Sep 1;76(9):1117-1145. doi: 10.1016/j.jacc.2020.05.037. Epub 2020 Aug 5.
2
Pericardial Adipose Tissue Volume Is Independently Associated With Human Immunodeficiency Virus Status and Prior Use of Stavudine, Didanosine, or Indinavir.心包脂肪组织体积与人类免疫缺陷病毒状态及先前使用司他夫定、去羟肌苷或茚地那韦独立相关。
J Infect Dis. 2020 Jun 16;222(1):54-61. doi: 10.1093/infdis/jiaa057.
3
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - .美国临床内分泌医师协会和美国内分泌学会关于2型糖尿病综合管理算法的共识声明 -
Endocr Pract. 2020 Jan;26(1):107-139. doi: 10.4158/CS-2019-0472.
4
11. Microvascular Complications and Foot Care: .11. 微血管并发症与足部护理：
Diabetes Care. 2020 Jan;43(Suppl 1):S135-S151. doi: 10.2337/dc20-S011.
5
10. Cardiovascular Disease and Risk Management: .10. 心血管疾病与风险管理： 。
Diabetes Care. 2020 Jan;43(Suppl 1):S111-S134. doi: 10.2337/dc20-S010.
6
9. Pharmacologic Approaches to Glycemic Treatment: .9. 血糖治疗的药物学方法： 。
Diabetes Care. 2020 Jan;43(Suppl 1):S98-S110. doi: 10.2337/dc20-S009.
7
5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: .5. 促进行为改变和幸福感以改善健康结果：。
Diabetes Care. 2020 Jan;43(Suppl 1):S48-S65. doi: 10.2337/dc20-S005.
8
2. Classification and Diagnosis of Diabetes: .2. 糖尿病的分类和诊断： 。
Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31. doi: 10.2337/dc20-S002.
9
Weight gain and integrase inhibitors.体重增加与整合酶抑制剂。
Curr Opin Infect Dis. 2020 Feb;33(1):10-19. doi: 10.1097/QCO.0000000000000616.
10
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.抗逆转录病毒治疗起始后体重增加：随机对照临床试验中的危险因素。
Clin Infect Dis. 2020 Sep 12;71(6):1379-1389. doi: 10.1093/cid/ciz999.
Zotero 插件